Posts

Afya Limited Announces Strong First-Quarter 2026 Financial Results

on

Recursion Reports Q1 2026 Financial Results and Business Update

on

CRISPR Therapeutics Reports Q1 2026 Financial Results with CASGEVY Revenue of $43M and $2.44B Cash Position

on

BioMarin Reports First Quarter 2026 Financial and Operating Results

on

Jasper Therapeutics Reports Q4 and Year-End 2025 Financial Results and Corporate Update

on

INmune Bio Inc. Announces 2025 Results and Provides Business Update

on

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

on

Light AI Reports Q4 and Full-Year 2025 Financial Results

on

BioPorto Announces 2025 Annual Report Release on March 26, 2026

on

Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

on

Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

on

Rakovina Therapeutics Q3 2025 Financial Results and Corporate Update

on

Immunome, Inc. Reports Third Quarter 2025 Financial Results and Business Update

on

Dianthus Therapeutics Q3 2025 Financial Results and Business Achievements

on

Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update

on

Pliant Therapeutics Q3 2025 Financial Results and Corporate Update

on

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

on

Dexcom Reports Strong Q4 and Full-Year 2025 Financial Results, Beats Estimates Despite Stock Dip

on

Immunome, Inc. Reports Q3 2025 Financial Results and Business Update

on

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2025 Financial Results

on